RESUMO
BACKGROUND: The survival effects of combined organ resection in cytoreductive surgery for advanced ovarian carcinoma with regard to the site and the number of organs involved have not yet been clarified. METHODS: Data obtained from 143 patients with stage III/IV ovarian carcinoma were used for analysis. Combined organ resection (COR) was employed in 21 patients in whom optimal cytoreduction (defined as a residuum Assuntos
Carcinoma/mortalidade
, Carcinoma/cirurgia
, Neoplasias Ovarianas/mortalidade
, Neoplasias Ovarianas/cirurgia
, Adulto
, Idoso
, Idoso de 80 Anos ou mais
, Protocolos de Quimioterapia Combinada Antineoplásica
, Carcinoma/tratamento farmacológico
, Carcinoma/patologia
, Estudos de Coortes
, Terapia Combinada
, Intervalo Livre de Doença
, Feminino
, Seguimentos
, Humanos
, Histerectomia/métodos
, Pessoa de Meia-Idade
, Estadiamento de Neoplasias
, Neoplasias Ovarianas/tratamento farmacológico
, Neoplasias Ovarianas/patologia
, Ovariectomia/métodos
, Exenteração Pélvica
, Probabilidade
, Estudos Retrospectivos
, Medição de Risco
, Taxa de Sobrevida
, Resultado do Tratamento
RESUMO
BACKGROUND: This study was conducted to investigate the recommended dose of paclitaxel for use in combination with a fixed dose of carboplatin and to evaluate the toxicity and efficacy of carboplatin-paclitaxel combination chemotherapy in patients with epithelial ovarian cancer. METHODS: One hundred and ten patients were enrolled in the Phase I/II study and 97 patients were evaluated for further analysis, excluding 13 ineligible patients or patients with infringement of protocol: 15 patients for the Phase I and 82 for the Phase II study. In the Phase I trial, we studied dose escalation using a carboplatin dose of AUC 5 and paclitaxel levels of 150, 175 and 200 mg/m(2). The grades of toxicity of the regimen of all patients enrolled in the Phase II study (n = 82), the progression-free survival time (PFS) of optimal-debulked patients and complete responders (n = 62) and the response rate of suboptimal-debulked patients (n = 39) were investigated. RESULTS: After observing grade 4 neutropenia in four of six patients in the paclitaxel 200 mg/m(2) administration group, we chose 175 mg/m(2) as the recommended dose of paclitaxel in this regimen. At this dose, the median of PFS and response rate were 432 days (range, 19-907 days) and 66.7%, respectively. CONCLUSION: Combination chemotherapy using paclitaxel 175 mg/m(2) and carboplatin AUC 5 is very well tolerated and highly effective for the treatment of ovarian cancer.